Although tremendous strides have been made towards understanding the basic biology of breast cancer, very few of these advances have directly translated into improved outcome for the breast cancer patient. Several reasons may account for the inability to turn research findings into clinical applications. 1. A successful translational breast cancer program requires several elements: a critical mass of basic scientists, breast cancer clinicians who function in a multi-disciplinary setting, administrative support, and adequate resources. The SPORE program was designed to facilitate the merging of these elements. 2. Research technology has become increasingly complex and specialized. This trend can limit the kinds of questions any individual investigator can ask, and collaboration between investigators is absolutely required. For example, if the chemotherapist wishes to investigate p53 mutation and response to chemotherapy, collaboration with a skilled molecular biologist will be necessary. The molecular biologist may wish to study breast cancer tissues, which requires collaboration with a breast cancer pathologist. Real advances in improving patient outcome will come from a collaborative team approach, drawing together the various basic science disciplines (molecular biology, cell biology, protein chemistry, etc.) and the clinical disciplines. 3. Research and clinical training has become highly specialized. The Ph.D. investigator often trains in a very narrow field of technology and application. Such training may leave the investigator ill-prepared to approach the complex clinical questions posed by the breast cancer patient. Similarly, the M.D. investigator can become narrowly focused in clinical areas such that the potential applications of basic research findings are not understood or utilized. In order to more rapidly translate basic science advances into clinical advances, a special type of investigator is required. There are still relatively few investigators who can operate at the critical interface between basic science research and clinical medicine. Several barriers evident in the current training of scientists may be responsible for this observation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058183-17
Application #
8208778
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
17
Fiscal Year
2011
Total Cost
$78,222
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Guven, Adem; Villares, Gabriel J; Hilsenbeck, Susan G et al. (2017) Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater 58:466-478
Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134

Showing the most recent 10 out of 306 publications